Images List Premium Download Classic

Isoquinolin

Isoquinolin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
[9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol ...
December 07, 2017 - N°20170349586

Wherein r1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (vmat2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.
Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
Epizyme, Inc.
November 23, 2017 - N°20170334861

Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity. Methods of using the compounds for treating prmt5-mediated disorders are also described.
Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
Epizyme, Inc.
November 09, 2017 - N°20170320871

And stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituent and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula i compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen ...
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Isoquinolin-3-yl carboxamides and preparation and use thereof
Epizyme, Inc.
November 02, 2017 - N°20170313682

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e. G., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by ...
Isoquinolin-3-yl carboxamides and preparation and use thereof
Epizyme, Inc.
November 02, 2017 - N°20170313681

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e. G., cancer, abnormal cellular proliferation, angiogenesis, alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated ...
Tyrosine hydroxylase variants and methods of use thereof
The Regents Of The University Of California
October 26, 2017 - N°20170306301

The present disclosure provides a variant tyrosine hydroxylase that provides for increased production of l-dopa in a host cell that expresses the tyrosine hydroxylase. The present disclosure provides nucleic acids encoding the variant tyrosine hydroxylase, and host cells genetically modified with the nucleic acids. The present disclosure provides methods of making l-dopa in a host cell. The present disclosure provides ...
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tetrahydroisoquinoline derivatives
Ucb Biopharma Sprl
October 26, 2017 - N°20170304292

The present invention relates to tetrahydroisoquinoline derivatives according to formula (i), which are positive allosteric modulators of d1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which d1 receptors play a role.
Method of washing textiles in a washing machine with activating unit
Ucb Biopharma Sprl
October 19, 2017 - N°20170298305

The disclosure relates to a method of washing textiles in a washing machine having a washing chamber for accommodating a washing liquid and textiles to be cleaned and having an activating unit possessing an inlet or introduction of washing liquid from the washing chamber into the activating unit and possessing an outlet for guiding washing liquid out of the activating ...
Tetrahydroisoquinoline derived prmt5-inhibitors
Ucb Biopharma Sprl
October 19, 2017 - N°20170298075

A compound of formula i wherein: n is 1 or 2: p is 0 or 1; r1 is optionally one or more halo or methyl groups; r2a and r2b are independently selected from the group consisting of: (i) f; (ii) h; (iii) me; and (iv) ch2oh; r2c and r2d are independently selected from the group consisting of: (i) f; (...
Substituted dihydroisoquinolinone compounds
Ucb Biopharma Sprl
October 19, 2017 - N°20170298048

In which r1, r2, r3, r4, l, x and z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
Corneal thickness adjustment agent
Kowa Company, Ltd.
October 12, 2017 - N°20170290840

The present invention provides a novel corneal thickness modulating agent. The present invention pertains to a corneal thickness modulating agent containing 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof or a solvate thereof.
Tetrahydroisoquinoline derived prmt5-inhibitors
Ctxt Pty Ltd
October 05, 2017 - N°20170283407

A compound of formula (i) wherein: r1 is optionally one or more halo or methyl groups; r2a and r2b are independently selected from the group consisting of: (i) f; (ii) h; (iii) me; and (iv) ch2oh; r2c and r2d are independently selected from the group consisting of: (i) f; (ii) h; (iii) me; and (iv) ...
Combination therapy
Aerie Pharmaceuticals, Inc.
October 05, 2017 - N°20170281613

Described herein are compounds and compositions for treating glaucoma and/or reducing introcular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together ...
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273966

The present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273965

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula (i) are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Drug combination
Verona Pharma Plc
September 21, 2017 - N°20170266190

The invention provides a composition which comprises (a) a pde3/pde4 inhibitor which is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.
Pharmaceutical product
Kowa Company, Ltd.
September 21, 2017 - N°20170266080

A technique is provided for suppressing discoloration of an aqueous composition containing a halogenated isoquinoline derivative during preservation at high temperature. A pharmaceutical preparation obtained by storing an aqueous composition comprising a compound represented by formula (1), wherein x represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, in a container made ...
Bi-benzyl isoquinoline derivative, preparation method and use thereof in hepatopathy treatment and prevention
Versitech Ltd.
September 14, 2017 - N°20170260161

The invention disclosed a compound of general formula (i), a single stereoisomer thereof, a mixture of stereoisomers thereof, and a prodrug, pharmaceutically acceptable salt and metabolite thereof, x1, x2, x3, x4, r1, r2, x, y and z being as defined in the present invention.
Noscapinoid-producing microbes and methods of making and using the same
The Board Of Trustees Of The Leland Stanford Junior University
September 07, 2017 - N°20170253898

Engineered non-plant cells that produce a benzylisoquinoline alkaloid product that is a derivative of canadine along a metabolic pathway that converts canadine, or an analog of canadine, to a noscapinoid product are provided. Methods of culturing engineered non-plant cells that produce a noscapinoid product and pharmaceutical compositions are also provided.
Isoquinolinone derivatives useful in the treatment of cancer
Pierre Fabre Medicament
August 24, 2017 - N°20170240544

The present invention relates to a compound of the following formula (i) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a compound and processes to prepare such a compound.
Liquid inhalation formulation comprising rpl554
Verona Pharma Plc
August 24, 2017 - N°20170239178

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one (rpl554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment ...
Loading